Proposed Collection; 60-Day Comment Request; Surveys and Interviews To Support an Evaluation of the Innovative Molecular Analysis Technologies (IMAT) Program (NCI), 72004-72005 [2014-28498]
Download as PDF
<![CDATA[
72004
Federal Register / Vol. 79, No. 233 / Thursday, December 4, 2014 / Notices
related questions with inquiries into the
communication channels through which
understanding is being obtained, and
assessment of FDA-regulated material.
This survey will extend the information
collected and priorities from HINTS
which have been to provide a
comprehensive assessment of the
American public’s current access to, and
use of, information about cancer across
the cancer care continuum from cancer
prevention, early detection, diagnosis,
treatment, and survivorship.
OMB approval is requested for 1 year.
There are no costs to respondents other
than their time. The total estimated
annualized burden hours are 2,159.
ESTIMATED ANNUALIZED BURDEN HOURS
Type of respondents
Number of
respondents
Number of
responses per
respondent
Average
burden per
response
(in hours)
Total annual
burden hour
Individuals ........................................................................................................
4,318
1
30/60
2,159
Dated: November 24, 2014.
Karla Bailey,
NCI Project Clearance Liaison, National
Institutes of Health.
[FR Doc. 2014–28513 Filed 12–3–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Proposed Collection; 60-Day Comment
Request; Surveys and Interviews To
Support an Evaluation of the
Innovative Molecular Analysis
Technologies (IMAT) Program (NCI)
In compliance with the
requirement of Section 3506(c)(2)(A) of
the Paperwork Reduction Act of 1995,
for opportunity for public comment on
proposed data collection projects, the
National Cancer Institute (NCI),
National Institutes of Health (NIH), will
publish periodic summaries of proposed
projects to be submitted to the Office of
Management and Budget (OMB) for
review and approval.
Written comments and/or suggestions
from the public and affected agencies
are invited on one or more of the
following points: (1) Whether the
proposed collection of information is
necessary for the proper performance of
the function of the agency, including
whether the information will have
practical utility; (2) The accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used; (3)
Ways to enhance the quality, utility, and
clarity of the information to be
collected; and (4) Ways to minimize the
burden of the collection of information
on those who are to respond, including
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:23 Dec 03, 2014
Jkt 235001
the use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology.
To Submit Comments and For Further
Information: To obtain a copy of the
data collection plans and instruments,
submit comments in writing, or request
more information on the proposed
project, contact: Anthony Dickherber,
NCI Center for Strategic Scientific
Initiatives, 31 Center Drive, Rm10A33,
Bethesda, MD 20892 or call non-toll-free
number 301–547–9980 or Email your
request, including your address to:
dickherberaj@mail.nih.gov. Formal
requests for additional plans and
instruments must be requested in
writing.
Comment Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60 days of the date of
this publication.
Proposed Collection: Surveys and
Interviews to Support an Evaluation of
the Innovative Molecular Analysis
Technologies (IMAT) Program (NCI),
0925–NEW, National Cancer Institute
(NCI), National Institutes of Health
(NIH).
Need and Use of Information
Collection: The purpose of the proposed
evaluation is to pursue a comprehensive
process and outcome assessment of the
15-year old Innovative Molecular
Analysis Technologies (IMAT) program.
While the program consistently offers
promising indicators of success, the full
program has not been evaluated since
2008, and never in as comprehensive a
manner as has been formulated in the
current evaluation plan. An outcome
evaluation of the long-standing National
Cancer Institute’s (NCI) IMAT program
presents a rich and unique opportunity
likely to serve institutes across the
PO 00000
Frm 00025
Fmt 4703
Sfmt 4703
National Institutes of Health (NIH), and
perhaps other federal agencies,
considering the costs and benefits of
directing resources towards supporting
technology development. An award
through the NIH Evaluation Set-Aside
program to support this evaluation, for
which NIH-wide relevance is a principle
element of determining merit for
support, is testament to this. The
evaluation serves as an opportunity to
gauge the impact of investments in
technology development and also to
assess the strengths and weaknesses of
phased innovation award mechanisms.
Like all institutes and centers (ICs) of
the NIH, NCI seeks opportunities for
improving their programs’ utility for the
broad continuum of researchers,
clinicians and ultimately patients. NCI
Director Harold Varmus and other
leadership across NCI, as well as the
NCI Board of Scientific Advisors, will
be the primary users of the evaluation
results. Findings are primarily intended
for considering the long-term strategy to
support innovative technology
development and how to more
efficiently translate emerging
capabilities through such technologies
into the promised benefits for cancer
research and clinical care. Interviews
with grantees, program officers, review
officers, and other NIH awardees make
up a crucial component of the
evaluation plan and will largely follow
set survey protocols. Specific near-term
aims include the use of this information
to consider the utility of continued
investment through existing
solicitations and in strategic planning
generally for institute support for
innovative technology development.
OMB approval is requested for 1 year.
There are no costs to respondents other
than their time. The total estimated
annualized burden hours are 575.
E:\FR\FM\04DEN1.SGM
04DEN1
72005
Federal Register / Vol. 79, No. 233 / Thursday, December 4, 2014 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Form name
Type of respondents
IMAT Awardee Interview ...................
Evaluation Web-based Survey ..........
IMAT Awardees ...............................
IMAT Awardees, and other NIH
Awardees (Comparison group).
Technology End-Users ....................
Tech End Users Interview .................
Dated: November 24, 2014.
Karla Bailey,
NCI Project Clearance Liaison, National
Institutes of Health.
1
30/60
100
450
50
1
30/60
25
FOR FURTHER INFORMATION CONTACT:
Giselle Hersh, Division of Workplace
Programs, SAMHSA/CSAP, Room 7–
1051, One Choke Cherry Road,
Rockville, Maryland 20857; 240–276–
2600 (voice), 240–276–2610 (fax).
Substance Abuse and Mental Health
Services Administration
Substance Abuse and Mental
Health Services Administration, HHS.
AGENCY:
ACTION:
Notice.
The Department of Health and
Human Services (HHS) notifies federal
agencies of the laboratories and
Instrumented Initial Testing Facilities
(IITF) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines). The
Mandatory Guidelines were first
published in the Federal Register on
April 11, 1988 (53 FR 11970), and
subsequently revised in the Federal
Register on June 9, 1994 (59 FR 29908);
September 30, 1997 (62 FR 51118);
April 13, 2004 (69 FR 19644); November
25, 2008 (73 FR 71858); December 10,
2008 (73 FR 75122); and on April 30,
2010 (75 FR 22809).
A notice listing all currently HHScertified laboratories and IITFs is
published in the Federal Register
during the first week of each month. If
any laboratory or IITF certification is
suspended or revoked, the laboratory or
IITF will be omitted from subsequent
lists until such time as it is restored to
full certification under the Mandatory
Guidelines.
If any laboratory or IITF has
withdrawn from the HHS National
Laboratory Certification Program (NLCP)
during the past month, it will be listed
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:23 Dec 03, 2014
Jkt 235001
The
Mandatory Guidelines were initially
developed in accordance with Executive
Order 12564 and section 503 of Public
Law 100–71. The ‘‘Mandatory
Guidelines for Federal Workplace Drug
Testing Programs,’’ as amended in the
revisions listed above, requires strict
standards that laboratories and IITFs
must meet in order to conduct drug and
specimen validity tests on urine
specimens for federal agencies.
To become certified, an applicant
laboratory or IITF must undergo three
rounds of performance testing plus an
on-site inspection. To maintain that
certification, a laboratory or IITF must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
Laboratories and IITFs in the
applicant stage of certification are not to
be considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines. A HHS-certified
laboratory or IITF must have its letter of
certification from HHS/SAMHSA
(formerly: HHS/NIDA), which attests
that it has met minimum standards.
In accordance with the Mandatory
Guidelines dated November 25, 2008
(73 FR 71858), the following HHScertified laboratories and IITFs meet the
minimum standards to conduct drug
and specimen validity tests on urine
specimens:
SUPPLEMENTARY INFORMATION:
Current List of HHS-Certified
Laboratories and Instrumented Initial
Testing Facilities Which Meet Minimum
Standards To Engage in Urine Drug
Testing for Federal Agencies
HHS-Certified Instrumented Initial
Testing Facilities
Gamma-Dynacare Medical Laboratories,
6628 50th Street NW., Edmonton, AB
Canada T6B 2N7, 780–784–1190
PO 00000
Frm 00026
Fmt 4703
Sfmt 4703
Total annual
burden hours
1
1
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Average
burden per
response
(in hours)
100
900
at the end and will be omitted from the
monthly listing thereafter.
This notice is also available on the
Internet at https://beta.samhsa.gov/
workplace.
[FR Doc. 2014–28498 Filed 12–3–14; 8:45 am]
Number of
responses per
respondent
HHS-Certified Laboratories
ACM Medical Laboratory, Inc., 160
Elmgrove Park, Rochester, NY 14624,
585–429–2264
Aegis Analytical Laboratories, Inc., 345
Hill Ave., Nashville, TN 37210, 615–
255–2400, (Formerly: Aegis Sciences
Corporation, Aegis Analytical
Laboratories, Inc., Aegis Analytical
Laboratories)
Alere Toxicology Services, 1111 Newton
St., Gretna, LA 70053, 504–361–8989/
800–433–3823, (Formerly: Kroll
Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.)
Alere Toxicology Services, 450
Southlake Blvd., Richmond, VA
23236, 804–378–9130, (Formerly:
Kroll Laboratory Specialists, Inc.,
Scientific Testing Laboratories, Inc.;
Kroll Scientific Testing Laboratories,
Inc.)
Baptist Medical Center-Toxicology
Laboratory, 11401 I–30, Little Rock,
AR 72209–7056, 501–202–2783,
(Formerly: Forensic Toxicology
Laboratory Baptist Medical Center)
Clinical Reference Lab, 8433 Quivira
Road, Lenexa, KS 66215–2802, 800–
445–6917
DrugScan, Inc., 200 Precision Road,
Suite 200, Horsham, PA 19044, 800–
235–4890
ElSohly Laboratories, Inc., 5 Industrial
Park Drive, Oxford, MS 38655, 662–
236–2609
Fortes Laboratories, Inc., 25749 SW.,
Canyon Creek Road, Suite 600,
Wilsonville, OR 97070, 503–486–1023
Gamma-Dynacare Medical
Laboratories *, A Division of the
Gamma-Dynacare Laboratory
Partnership, 245 Pall Mall Street,
London, ONT, Canada N6A 1P4, 519–
679–1630
Laboratory Corporation of America
Holdings, 7207 N. Gessner Road,
Houston, TX 77040, 713–856–8288/
800–800–2387
Laboratory Corporation of America
Holdings, 69 First Ave., Raritan, NJ
08869, 908–526–2400/800–437–4986,
(Formerly: Roche Biomedical
Laboratories, Inc.)
Laboratory Corporation of America
Holdings, 1904 Alexander Drive,
E:\FR\FM\04DEN1.SGM
04DEN1
]]>Agencies
[Federal Register Volume 79, Number 233 (Thursday, December 4, 2014)]
[Notices]
[Pages 72004-72005]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-28498]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Proposed Collection; 60-Day Comment Request; Surveys and
Interviews To Support an Evaluation of the Innovative Molecular
Analysis Technologies (IMAT) Program (NCI)
SUMMARY: In compliance with the requirement of Section 3506(c)(2)(A) of
the Paperwork Reduction Act of 1995, for opportunity for public comment
on proposed data collection projects, the National Cancer Institute
(NCI), National Institutes of Health (NIH), will publish periodic
summaries of proposed projects to be submitted to the Office of
Management and Budget (OMB) for review and approval.
Written comments and/or suggestions from the public and affected
agencies are invited on one or more of the following points: (1)
Whether the proposed collection of information is necessary for the
proper performance of the function of the agency, including whether the
information will have practical utility; (2) The accuracy of the
agency's estimate of the burden of the proposed collection of
information, including the validity of the methodology and assumptions
used; (3) Ways to enhance the quality, utility, and clarity of the
information to be collected; and (4) Ways to minimize the burden of the
collection of information on those who are to respond, including the
use of appropriate automated, electronic, mechanical, or other
technological collection techniques or other forms of information
technology.
To Submit Comments and For Further Information: To obtain a copy of
the data collection plans and instruments, submit comments in writing,
or request more information on the proposed project, contact: Anthony
Dickherber, NCI Center for Strategic Scientific Initiatives, 31 Center
Drive, Rm10A33, Bethesda, MD 20892 or call non-toll-free number 301-
547-9980 or Email your request, including your address to:
dickherberaj@mail.nih.gov. Formal requests for additional plans and
instruments must be requested in writing.
Comment Due Date: Comments regarding this information collection
are best assured of having their full effect if received within 60 days
of the date of this publication.
Proposed Collection: Surveys and Interviews to Support an
Evaluation of the Innovative Molecular Analysis Technologies (IMAT)
Program (NCI), 0925-NEW, National Cancer Institute (NCI), National
Institutes of Health (NIH).
Need and Use of Information Collection: The purpose of the proposed
evaluation is to pursue a comprehensive process and outcome assessment
of the 15-year old Innovative Molecular Analysis Technologies (IMAT)
program. While the program consistently offers promising indicators of
success, the full program has not been evaluated since 2008, and never
in as comprehensive a manner as has been formulated in the current
evaluation plan. An outcome evaluation of the long-standing National
Cancer Institute's (NCI) IMAT program presents a rich and unique
opportunity likely to serve institutes across the National Institutes
of Health (NIH), and perhaps other federal agencies, considering the
costs and benefits of directing resources towards supporting technology
development. An award through the NIH Evaluation Set-Aside program to
support this evaluation, for which NIH-wide relevance is a principle
element of determining merit for support, is testament to this. The
evaluation serves as an opportunity to gauge the impact of investments
in technology development and also to assess the strengths and
weaknesses of phased innovation award mechanisms.
Like all institutes and centers (ICs) of the NIH, NCI seeks
opportunities for improving their programs' utility for the broad
continuum of researchers, clinicians and ultimately patients. NCI
Director Harold Varmus and other leadership across NCI, as well as the
NCI Board of Scientific Advisors, will be the primary users of the
evaluation results. Findings are primarily intended for considering the
long-term strategy to support innovative technology development and how
to more efficiently translate emerging capabilities through such
technologies into the promised benefits for cancer research and
clinical care. Interviews with grantees, program officers, review
officers, and other NIH awardees make up a crucial component of the
evaluation plan and will largely follow set survey protocols. Specific
near-term aims include the use of this information to consider the
utility of continued investment through existing solicitations and in
strategic planning generally for institute support for innovative
technology development.
OMB approval is requested for 1 year. There are no costs to
respondents other than their time. The total estimated annualized
burden hours are 575.
[[Page 72005]]
Estimated Annualized Burden Hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden per Total annual
Form name Type of respondents respondents responses per response (in burden hours
respondent hours)
--------------------------------------------------------------------------------------------------------------------------------------------------------
IMAT Awardee Interview......................... IMAT Awardees.......................... 100 1 1 100
Evaluation Web-based Survey.................... IMAT Awardees, and other NIH Awardees 900 1 30/60 450
(Comparison group).
Tech End Users Interview....................... Technology End-Users................... 50 1 30/60 25
--------------------------------------------------------------------------------------------------------------------------------------------------------
Dated: November 24, 2014.
Karla Bailey,
NCI Project Clearance Liaison, National Institutes of Health.
[FR Doc. 2014-28498 Filed 12-3-14; 8:45 am]
BILLING CODE 4140-01-P
